anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
There is limited clinical experience with Savella overdose in humans. In clinical trials, cases of acute ingestions up to 1000 mg, alone or in combination with other drugs, were reported with none being fatal. 

In postmarketing experience, fatal outcomes have been reported for acute overdoses primarily involving multiple drugs but also with Savella only. The most common signs and symptoms included increased blood pressure, cardio-respiratory arrest, changes in the level of consciousness (ranging from somnolence to coma), confusional state, dizziness, and increased hepatic enzymes. 

Management of Overdose

There is no specific antidote to Savella, but if serotonin syndrome ensues, specific treatment (such as with cyproheptadine and/or temperature control) may be considered. In case of acute overdose, treatment should consist of those general measures employed in the management of overdose with any drug. 

An adequate airway, oxygenation, and ventilation should be assured and cardiac rhythm and vital signs should be monitored. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion or in symptomatic patients. Because there is no specific antidote for Savella, symptomatic care and treatment with gastric lavage and activated charcoal should be considered as soon as possible for patients who experience a Savella overdose. 

Due to the large volume of distribution of this drug, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be beneficial. 

In managing overdose, the possibility of multiple drug involvement should be considered. The physician should consider contacting a poison control center for additional information on the treatment of any overdose. Telephone numbers for certified poison control centers are listed in the Physicians' Desk Reference (PDR).
PARP Inhibitor-Naive Platinum-Resistant Ovarian Cancer Treatment Cohort with TSR-042, Bevacizumab, and Niraparib. TSR-042 administered 500 milligrams (mg) on Day 1 every 3 weeks (Q3W) for 4 cycles (each cycle is 21 days), followed by 1000 mg every 6 weeks (Q6W) beginning on Cycle 5 Day 1 until progressive disease (PD) or toxicity. Bevacizumab administered 15 milligram per kilogram (mg/kg) every 3 weeks for up to 15 months. Niraparib 200 or 300 mg per day until PD or toxicity.
We plan to study 10 male participants with moderate obstructive sleep apnea (OSA) and 10 male control participants matched for age, race and body mass index. The OSA and control participants will be exposed to intermittent hypoxia during wakefulness and sleep following administration of an antioxidant or a placebo cocktail that will be presented in a randomized fashion.
The invention provides a method for identifying a characteristic of one or more ultrasound images, wherein each image is of a subject imaged by an ultrasound probe using an ultrasound imaging process. The method includes obtaining a manipulation signal indicative of a manipulation of the ultrasound probe during the imaging process. A portion of the manipulation signal, which indicates the manipulation of the probe during a time period, is obtained. The obtained portion is associated with one or more ultrasound images. A neural network system is then used to classify a characteristic of the one or more ultrasound images based on both the obtained portion of the manipulation signal and the one or more images themselves. Such classification comprises applying one or more convolution kernels on the obtained portion of the manipulation signal to generate a convolution output representative of the obtained portion of the manipulation signal, and classifying the convolution output to indicate the characteristic of the one or more ultrasound images associated with the obtained portion.
The recommended adult oral dose of misoprostol for reducing the risk of NSAID-induced gastric ulcers is 200 mcg four times daily with food. If this dose cannot be tolerated, a dose of 100 mcg can be used. (See Clinical Pharmacology: Clinical studies.) Misoprostol should be taken for the duration of NSAID therapy as prescribed by the physician. Misoprostol should be taken with a meal, and the last dose of the day should be at bedtime.

  


Renal impairment

Adjustment of the dosing schedule in renally impaired patients is not routinely needed, but dosage can be reduced if the 200-mcg dose is not tolerated. (See Clinical Pharmacology.)
T-2 toxin, an omnipresent environmental contaminant, poses a serious risk to the health of humans and animals due to its pronounced cardiotoxicity. This study aimed to elucidate the molecular mechanism of cardiac tissue damage by T-2 toxin. Twenty-four male Sprague-Dawley rats were orally administered T-2 toxin through gavage for 12 weeks at the dose of 0, 10, and 100 nanograms per gram body weight per day (ng/(g·day)), respectively. Morphological, pathological, and ultrastructural alterations in cardiac tissue were meticulously examined. Non-targeted metabolomics analysis was employed to analyze alterations in cardiac metabolites. The expression of the Sirt3/FoxO3α/MnSOD signaling pathway and the level of oxidative stress markers were detected. The results showed that exposure to T-2 toxin elicited myocardial tissue disorders, interstitial hemorrhage, capillary dilation, and fibrotic damage. Mitochondria were markedly impaired, including swelling, fusion, matrix degradation, and membrane damage. Metabonomics analysis unveiled that T-2 toxin could cause alterations in cardiac metabolic profiles as well as in the Sirt3/FoxO3α/MnSOD signaling pathway. T-2 toxin could inhibit the expressions of the signaling pathway and elevate the level of oxidative stress. In conclusion, the T-2 toxin probably induces cardiac fibrotic impairment by affecting amino acid and choline metabolism as well as up-regulating oxidative stress mediated by the Sirt3/FoxO3α/MnSOD signaling pathway. This study is expected to provide targets for preventing and treating T-2 toxin-induced cardiac fibrotic injury.
Beverage (100 mL) containing pineapple juice, lime juice and water. Nightly for 10 days.
1,143,589. 2 - Amino - 4 - hydroxytoluene. L'OREAL. 7 April, 1966 [6 May, 1965], No. 3274/68. Divided out of 1,143,588. Heading C2C. 2 - Amino - 4 - hydroxytoluene is prepared by reacting p-cresol with a compound capable of protecting the phenol function, nitrating the benzene ring of the reaction product in mposition with respect to the protected phenol function, reducing the nitro group to an amino group and then liberating the phenol function. In the example 4-hydroxytoluene is reacted with methane sulphochloride, the mesylated product is dissolved in sulphuric acid and nitrated with a mixture of nitric and sulphuric acids, the nitrated product is reduced with tin and hydrochloric acid and the amino compound produced is hydrolysed with sodium hydroxide to obtain 2-amino-4-hydroxy-toluene.
PURPOSE:To provide the titled dentifrice composition having improved shape- retainability, stringiness and feeling to the palate, by adding a water-soluble alkaline earth metal salt to a dentifrice composition containing a non-calcium abrasive and a carboxymethylcellulose alkali metal salt as a binder. CONSTITUTION:A dentifrice composition containing a non-calcium abrasive as an abrasive and a carboxymethylcellulose alkali metal salt as a binder, is compounded with preferably 0.01-5wt%, especially 0.1-2wt% water-soluble alkaline metal salt. The thickening effect of the dentifrice can be increased and the feeling to the palate can be improved by adding a water-soluble phosphate such as dipotassium phosphate, etc. to the water-soluble alkaline earth metal salt. The amount of the water-soluble phosphate is preferably 0.1-0.5%, and that of the abrasive is preferably 20-40% of the whole composition. The binder is preferably the one having a molecular weight of 30,000-80,000 and an etherification degree of 0.7-0.9.
The present document describes a training method of a machine learning data processing model for determining a hypoxia status of a neoplasm, in particular a random forest model. The method comprises obtaining, for a plurality of neoplasms, at least one data sample comprising 3D imaging data. A hypoxic volume fraction is determined for each data sample, as well as a set of image features associated With the neoplasm. The method further iterates a sequence of training steps and each iteration includes: selecting a subset of image features and eliminating, for each data sample, the subset of image features to yield a reduced set of image features. The iteration also includes generating decision trees, providing a momentary random forest model based thereon, and submitting a test set of image features to the momentary random forest model to yield a performance value. The iterations are continued until all image features have been selected for a subset at least once, and then a plurality of preferred image features are selected for providing a radiomics feature signature. The trained random forest data processing model based on decision trees associated With the preferred image features of the radiomics feature signature.
PURPOSE: To determine if body mass index (BMI) and adipokine levels identify rheumatoid arthritis (RA) patients most likely to benefit from initiation of tumour necrosis factor inhibitors (TNFi) after methotrexate inadequate response.
METHODS: This is a secondary analysis of the Rheumatoid Arthritis Comparison of Active Treatments (RACAT) trial and the (TEAR) trial. Both studies compared treatment strategies starting with conventional disease-modifying anti-rheumatic drugs (DMARDs) (triple therapy) versus etanercept plus methotrexate. We compared response rates between TNFi and triple therapy among patients with different BMI. Adipokines were measured at enrolment and associations with treatment response were examined using regression, adjusting for age, sex, BMI and baseline disease activity.
RESULTS: In RACAT (n=306), participants who were normal/underweight were more likely to benefit from TNFi versus triple therapy, with greater change in Disease Activity Score in 28 and greater ACR20 response (ACR 20: 64% vs 23%, p=0.001). In contrast, overweight/obese participants had similar response to TNFi versus triple therapy (p-for-interaction=0.001). Similarly, but modest patterns were observed in TEAR (n=601; ACR20: 67% vs 52%, p=0.05). In RACAT, adipokine scores consistent with lower adiposity also predicted greater response to TNFi (ACR20: 58% vs 37%, p=0.01) with better model fit compared with BMI alone.
CONCLUSIONS: Lower BMI and evidence of lower adiposity based on adipokine profiles were associated with a superior response to TNFi compared with triple therapy. There was no difference between treatments among overweight/obese participants. The results support TNFi being a particularly important therapeutic among normal/underweight patients, with implications for clinical decisions and trial design.
The present invention relates to a novel plaster formula and a preparation process thereof. The plaster which can treat pain in necks, shoulders, waists and legs, arthritis and neuralgia is developed based on Chinese medical theories combined with clinical practice for many years. The formula selects more than 50 kinds of high quality traditional Chinese medicine comprising datura flower, white mustard seed, notoginseng powder, raw aconite root, radix aconiti, raw vomiting nut, centipedes, asarone, kaempferol, garter snake, rhizoma drynariae, wooly datchmanspipe herb, ephedra, spatholobus stem, angelica, notoperygium root, earthworm, ground beetle, etc. Substrates are decocted, thick medicinal paste is prepared, fine medicinal powder is ground, and the plaster is processed by a series of processes of the decoction of the substrates, the preparation of the thick medicinal paste, the grinding of the fine medicinal powder, spread and coating. The plaster has an effective rate of more than 97% through clinical practice for many years and is deeply welcomed by patients. The present invention provides a novel plaster with popularization value and a preparation process thereof.
INTRODUCTION: Elderly patients are at a high risk of postoperative delirium (POD), leading to increased postoperative morbidity and mortality. The use of dexmedetomidine and depth of anaesthesia may influence POD. This study aims to determine the effects of dexmedetomidine infusion versus normal saline placebo during light versus deep anaesthesia on POD among elderly patients undergoing major non-cardiac surgery.
METHODS AND ANALYSIS: This prospective, multicentre, randomised, controlled, factorial trial will be conducted at three tertiary hospitals in Jiangsu, China. We will recruit a total of 420 patients who are at least 60 years old and undergoing major non-cardiac surgery (thoracic, abdominal, urology, orthopaedic and spine surgery) under general anaesthesia. Patients will be randomised (1:1:1:1) to receive one of four anaesthesia regimens: (1) dexmedetomidine and light anaesthesia, (2) dexmedetomidine and deep anaesthesia, (3) placebo and light anaesthesia or (4) placebo and deep anaesthesia. Dexmedetomidine will be infused at 0.5 µg/kg/h throughout surgery, and intraoperative bispectral index target will be 55 for light anaesthesia and 40 for deep anaesthesia. The primary outcome is the occurrence of POD during the first 7 days postoperatively or until hospital discharge, assessed using the 3-min Confusion Assessment Method two times per day. The secondary outcomes include days with POD, type of POD, pain scores at rest and on movement at 24 and 48 hours postoperatively, patient-controlled intravenous fentanyl consumption during 0-24 and 24-48 hours postoperatively, hypotension, bradycardia, postoperative nausea and vomiting, non-delirium complications, length of postoperative hospital stay, 30-day cognitive function and 30-day mortality. Data will be analysed on a modified intention-to-treat basis.
ETHICS AND DISSEMINATION: This trial was approved by the Ethics Committee of the First Affiliated Hospital of Soochow University and each participating centre. The trial results will be published in a peer-reviewed journal.
TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR2300073271).
All patients will be instructed to exercise and lose weight according to the NCEP-ATP III diet. The participants will be randomized in an open manner into one of the following 2 treatment groups: a) cholecalciferol (VitD3) (2200 IU/day) plus lifestyle measures or b) only lifestyle measures. Recruitment will be completed within one year. The reassessment of the patients will be done 3 months after starting of treatment.
Subject will receive gemcitabine/abraxane with preoperatively paricalcitol. Patients randomized to receive paricalcitol pre-operatively will begin treatment with intravenous paricalcitol at 25 μg three times weekly for one cycle beginning day 1 of therapy until the day before surgery (+/- 3 days).
Provided are bovine intestinal mucosa enoxaparin sodium, a preparation method therefor, and an application thereof. The bovine intestinal mucosa enoxaparin sodium is prepared from bovine intestinal mucosa heparin. Being different from enoxaparin sodium that derives from porcine intestinal mucosa heparin and is stipulated by pharmacopeias such as the USP 39 and the EP 8.6, the bovine intestinal mucosa enoxaparin sodium presents typical species and organ source (bovine intestinal mucosa) features. Also provided are two types of bovine intestinal mucosa enoxaparin sodium injections and preparation methods therefor, and applications in anticoagulation experiments inside animals. The bovine intestinal mucosa enoxaparin sodium has the halal property that is not owned by porcine enoxaparin sodium, thereby having great markets in wide Moslem population, countries, and regions. The bovine intestinal mucosa enoxaparin sodium and injections thereof can be applied to anticoagulant, anti-thrombus, anti-inflammatory, anticancer,   and halal medicine.
BACKGROUND AND AIMS: systolic and diastolic blood pressure values identify different subtypes of Primary Hypertension. In pediatric age, hypertension is often related to obesity. Characterization of an individual's Blood Pressure (BP) status needs multiple measurements in the course of time, but this is rarely the case, principally in everyday pediatrics. Thus, the finding of abnormal BP values even in a single routine check visit should need a special attention. The aim of this study was to evaluate if even a single abnormal measurement could be a marker of metabolic risk, according to clinical and/or metabolic phenotype and subtypes of hypertension in a population of overweight/obese children and adolescents.
METHODS AND RESULTS: We reviewed data from 489 overweight-obese children and adolescents. BP values were classified according to American Academy of Pediatrics Guidelines (2017). Considering study design, we used the term "Abnormal" instead of "High" BP. Data on lipid profile, glucose metabolism and ultrasonographic pattern of the liver were recorded. Mean age was 9.4 ± 2.5 years: 76.9% had normal BP values. Children with Abnormal BP harbored more frequently an unfavorable metabolic profile. Children with Abnormal Systolic-Diastolic BP values had higher BMI z-score and Waist to Height ratio (p = 0.022 and p = 0.032). Hepatic Steatosis was detected in 4.5%, 14.8 % and 17.6 % of children with normal, abnormal systolic and abnormal systo-diastolic blood pressure, respectively. (p < 0.001).
CONCLUSION: Identification of abnormal BP subtypes even in a single measurement could be useful for identification of specific clinical-metabolic phenotypes allowing an individual targeted management of obesity-related comorbidities.
<P>PROBLEM TO BE SOLVED: To provide a β-endorphin production accelerator applicable to various skin symptoms by finding a component which accelerates the production of β-endorphin.  <P>SOLUTION: Rose water is used as the β-endorphin production accelerator which exhibits an excellent effect. The obtained β-endorphin production accelerator can give a relaxing effect on the skin and can prevent or improve various skin symptoms caused by stress by accelerating the production of β-endorphin in the skin. Particularly, it can prevent and improve skin symptoms based on cell activation action and whitening action. The skin symptoms which can be prevented and improved by this β-endorphin production accelerator include, for example, wrinkles, sagging, blotchiness, darkness, dryness, and roughness.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
All eligible participants will have the LNG-IUD. Experimental participants will also receive norethindrone acetate 5 mg by mouth daily for 12 months.
The invention discloses a 1,8 naphthalimide derivative and a preparation method and application thereof. The invention takes 4-bromine-1, 8-naphthalic anhydride as an initial raw material to carry out nucleophilic substitution reaction with 5-substituted benzotriazole to obtain an intermediate a-c; the intermediates a-c are reacted with 3 different diamine compounds to form naphthalimides, yielding the target products 1a-3c of formula (I). Wherein: r  1  Is hydrogen, fluorine or chlorine; r  2  Is dimethylamino, diethanol amino or piperazinyl. The cytotoxicity of different tumor cells of all target compounds is evaluated by a CCK-8 experimental technology, and the compound 3a with better activity is used for researching the action of the compound with a human B-lymphocytoma-2 protooncogene (Bcl-2) DNA sequence. The compound can well act on human proto-oncogene Bcl-2Pu39DNA rich birdsPurine G sequence can stabilize Bcl-2G-quadruplex structure. The invention provides a direction for discovering new anti-tumor small molecule drugs, in particular for the research and development of clinical drugs of 1,8 naphthalimide derivatives targeting Bcl-2.
The dose and schedule of AUY922 is the MTD dose identified in the phase I, given as 1 hour infusion weekly.

The Phase II component will have a 2 stage design single arm design. (Section 9.0). Overall response rate (ORR) is the primary endpoint. Estimated N=40 (12 in first stage) .A total of 39 response-evaluable participants is required. In the first stage, 12 response-evaluable participants will be accrued; if there are 3 or fewer CR+PRs, the study will stop for futility. There is a 55% probability of stopping early if, in fact, the ORR is 28%. If there are 4 or more CR+PRs, the study will proceed to the second stage and an additional 27 response-evaluable participants will be accrued. We will accrue 1 additional patient (then the needed 39 to account for attrition)
<P>PROBLEM TO BE SOLVED: To provide a natural product-originated fat absorption inhibitor mild in action with high safety even ingested over a long period.  <P>SOLUTION: This fat absorption inhibitor is formulated with a seed of Benincasa carifera. Excess ingestion of fat causes obesity and serum hypertriglyceridemia. Obesity raises insulin resistance, and it is known that obesity triggers high developing rate of diabetes mellitus, hyperlipemia, hypertension and arteriosclerotic diseases. Thus, agents suppressing fat absorption in food are effective for prophylaxis or amelioration of obesity and serum hypertriglyceridemia, and are thought to prevent diabetes mellitus, hyperlipemia, hypertension and arteriosclerotic diseases induced by obesity.  <P>COPYRIGHT: (C)2011,JPO&INPIT
BACKGROUND & AIMS: There is a lack of a meta-analysis to comprehensively assess the effectiveness of higher protein intake in addition to the recommended value on body composition post-bariatric surgery. We aimed to perform a meta-analysis of randomized controlled trials to determine the effects of protein intake higher than the recommended value on body composition changes after bariatric surgery.
METHODS: Electronic databases, including Scopus, PubMed/Medline, and Web of Sciences, were searched until July 2023. Studies that assessed the effect of protein intake higher than the recommended value on postoperative body composition, i.e., weight, body mass index (BMI), fat mass (FM), fat-free mass (FFM), percent fat mass (PFM), and percent total weight loss (%TWL), were eligible. For each outcome, the mean and standard deviation (for changes from baseline) were used to synthesize the data.
RESULTS: Eight trials were included in the current study. The results of the meta-analysis indicated protein intake higher than the recommended value after bariatric surgery led to more weight loss by 4.95 kg (95 % CI: -9.41 to -0.49) and FM loss by 7.64 kg (95 % CI: -14.01 to -1.28) compared with the control group. However, it had no significant effects on postoperative changes in BMI, FFM, PFM, or %TWL. There were no significant differences in body composition between protein sources obtained from diet and supplementation. When data was stratified based on the amount of added protein, we found a significant reduction in weight (MD: -7.80 kg; 95 % CI: -14.50 to -1.10) in patients who consumed protein ≥ 40 g/d in addition to the recommended value. Besides, protein intake higher than the recommended value declined FFM loss in patients who underwent laparoscopic sleeve gastrectomy (LSG) (MD: 6.52 kg; 95 % CI: 0.99 to 12.02).
CONCLUSION: The results of the current meta-analysis indicated that protein intake higher than the recommended value might cause greater weight and FM loss after bariatric surgery than a normal protein diet. However, our findings did not support the role of additional protein in the preservation of FFM, except in patients with LSG.